dalfampridine - Profile

What are the generic drug sources for dalfampridine and what is the scope of freedom to operate?

Dalfampridine is the generic ingredient in two branded drugs marketed by Merz, Accord Hlthcare, Actavis Labs Fl Inc, Alkem Labs Ltd, Aurobindo Pharma, Hikma, Micro Labs, Rising, and Sun Pharm, and is included in nine NDAs. Additional information is available in the individual branded drug profile pages.

There is one tentative approval for this compound.

Summary for dalfampridine

US Patents:	0
Tradenames:	2
Applicants:	9
NDAs:	9
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for dalfampridine

Generic filers with tentative approvals for DALFAMPRIDINE

Applicant	Application No.	Strength	Dosage Form
		10MG	TABLET, EXTENDED RELEASE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for DALFAMPRIDINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AMPYRA	Extended-release Tablets	dalfampridine	10 mg	022250	8	2014-01-22

US Patents and Regulatory Information for dalfampridine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merz	AMPYRA	dalfampridine	TABLET, EXTENDED RELEASE;ORAL	022250-001	Jan 22, 2010	AB	RX	Yes	Yes
Accord Hlthcare	DALFAMPRIDINE	dalfampridine	TABLET, EXTENDED RELEASE;ORAL	206863-001	Jul 11, 2018	AB	RX	No	No
Actavis Labs Fl Inc	DALFAMPRIDINE	dalfampridine	TABLET, EXTENDED RELEASE;ORAL	206836-001	Jan 23, 2017	AB	RX	No	No
Alkem Labs Ltd	DALFAMPRIDINE	dalfampridine	TABLET, EXTENDED RELEASE;ORAL	206765-001	Jul 30, 2018	AB	RX	No	No

Expired US Patents for dalfampridine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merz	AMPYRA	dalfampridine	TABLET, EXTENDED RELEASE;ORAL	022250-001	Jan 22, 2010	8,663,685
Merz	AMPYRA	dalfampridine	TABLET, EXTENDED RELEASE;ORAL	022250-001	Jan 22, 2010	5,370,879
Merz	AMPYRA	dalfampridine	TABLET, EXTENDED RELEASE;ORAL	022250-001	Jan 22, 2010	9,918,973
Merz	AMPYRA	dalfampridine	TABLET, EXTENDED RELEASE;ORAL	022250-001	Jan 22, 2010	8,440,703

Last updated: February 10, 2026

What Is Dalfampridine and What Is Its Market Position?

Dalfampridine (also known as fampridine in the United States, under brand name Ampyra) is an orally administered potassium channel blocker. It is primarily indicated to improve walking in patients with multiple sclerosis (MS). Originally approved by the U.S. Food and Drug Administration (FDA) in 2010, the drug has a marketed focus on symptom management rather than disease modification.

The global MS market size was estimated at $21 billion in 2022, with symptom-specific treatments like dalfampridine accounting for a smaller segment. Its primary competitors include disease-modifying therapies (DMTs), but there is limited competition in the symptomatic walking impairment space.

---

What Are the Financial and Patent Outlooks for Dalfampridine?

Patent Status: Dalfampridine has lost exclusivity in some markets, with patent expiries as early as 2018 in the U.S. and 2019 in Europe. No recent patent extensions or new formulations have been filed, exposing it to generic competition.

Pricing and Revenue: The drug's average wholesale price (AWP) in the U.S. ranged from $300–$400 per month per patient pre-generic entry, with current prices below $50 following generic competition. Peak sales, prior to generic entry, were estimated at approximately $400 million annually in the U.S.

Market Penetration: Approximately 1 million MS patients worldwide, with roughly 10–15% qualifying for and using dalfampridine therapy. Actual prescriptions are lower, reflecting cautious adoption and limited awareness.

Generic Competition and Price Decline: Generic versions issued from late 2018 have resulted in price erosion, decreasing revenue potential and reducing profit margins for original manufacturers.

---

What Are the R&D and Regulatory Fundamentals?

Clinical Development: Dalfampridine's approval was based on clinical trials demonstrating modest improvements in walking speed over placebo. No subsequent large-scale trials for new indications or formulations have been reported, indicating limited R&D pipeline activity.

Regulatory Landscape: The drug's primary approvals were granted based on efficacy in MS walking impairment, with no recent submissions for new indications. The lack of developmental activity suggests minimal regulatory risk unless reformulations or new indications emerge.

Research Gaps: Pending research includes potential neuroprotective applications, but no formal development programs are known. The absence of significant ongoing R&D reduces future revenue prospects but limits compliance and regulatory risks pertaining to new clinical data.

---

What Are the Investment Risks and Opportunities?

Risks

• Patent Expiry and Generic Competition: Entry of generics significantly depresses revenue.
• Limited Indications: The drug's narrow use case constrains growth opportunities.
• Market Saturation: Small patient base and slow adoption hinder expansion.
• Regulatory Uncertainty for Reformulations: Any attempts to broaden indications or develop new formulations face uncertain approval pathways.

Opportunities

• Potential for New Indications: Explorations for neuroprotective or cognitive benefits may open new markets.
• Combination Therapies: Combining dalfampridine with other MS treatments could enhance efficacy.
• Biotech Partnerships: Collaborations might accelerate innovation or patent extensions via formulation improvements.

---

What Is the Current Investment Outlook?

The financial outlook for dalfampridine is negative for long-term revenue growth unless new indications, formulations, or markets are developed. The primary value lies in existing patents and sales before generic entry, with most revenue erosion imminent. There may be niche opportunities through biosimilars or niche market re-entry, but these are uncertain and require regulatory approval.

---

Key Takeaways

• Dalfampridine is an MS symptom management drug with peak U.S. sales around $400 million prior to patent expiration.
• Patent losses since 2018 led to widespread generic competition and sharp price declines.
• No recent clinical development or new indications have emerged, limiting growth prospects.
• Investment in dalfampridine faces high risks from patent expiration, market saturation, and limited indications.
• Future upside depends on discovering new therapeutic uses or reformulation strategies.

---

FAQs

1. Can dalfampridine be repurposed for other neurological conditions?
Potential exists, but no current clinical trials are in progress. Significant regulatory and clinical hurdles remain.

2. What are the main competitors to dalfampridine?
Primarily, no direct competitors exist in symptom management for walking impairment in MS. However, emerging therapies for MS may indirectly impact its market share.

3. What is the outlook for patent extensions or exclusivity?
Rarely granted post-expiry, and no further patent extensions are reported. The drug is largely genericized in major markets.

4. Are there biosimilar or generic versions licensed?
Yes, generics entered the U.S. and EU markets starting in 2018–2019, reducing revenues for original manufacturers.

5. Could reformulation or combination therapies revive its market?
Possible but unconfirmed. Regulatory approval pathways would be required, and no such initiatives are publicly known.

---

Sources:
[1] IQVIA, 2023. MS Market Data.
[2] FDA, 2010. Approval of Fampridine.
[3] GlobalData, 2022. MS Drug Market Overview.
[4] Asche, et al., 2019. Patent Trends in CNS Drugs.